Acazicolcept Biosimilar – Anti-CD28 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA1999; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Acazicolcept Biosimilar is a novel fusion protein that has been developed as a biosimilar of the anti-CD28 antibody. The structure of this fusion protein is composed of two distinct domains: the anti-CD28 antibody domain and the therapeutic target domain. The anti-CD28 antibody domain is derived from a monoclonal antibody that specifically binds to the CD28 receptor on T cells. This domain is responsible for the binding and activation of the CD28 receptor. The therapeutic target domain is a fusion of the CD28 receptor and a specific therapeutic protein, which allows for targeted delivery of the therapeutic protein to the CD28 receptor.
The main activity of Acazicolcept Biosimilar is to target and bind to the CD28 receptor on T cells. This binding leads to the activation of the CD28 receptor, which in turn activates T cells. The activation of T cells plays a crucial role in the immune response, as it leads to the proliferation and differentiation of T cells, as well as the production of cytokines. Additionally, the fusion of the CD28 receptor with a therapeutic protein allows for the targeted delivery of the therapeutic protein to the CD28 receptor, enhancing its activity.
Acazicolcept Biosimilar has been developed for research purposes and is not yet approved for clinical use. However, it has the potential to be used as a therapeutic agent in the treatment of various diseases, including autoimmune disorders, cancer, and infectious diseases. The targeted delivery of the therapeutic protein to the CD28 receptor allows for a more specific and effective treatment, with fewer side effects.
One potential application of Acazicolcept Biosimilar is in the treatment of autoimmune disorders. The CD28 receptor is known to play a critical role in the activation and regulation of T cells, which are involved in the pathogenesis of autoimmune diseases. By targeting and activating the CD28 receptor, Acazicolcept Biosimilar can modulate the immune response and potentially treat autoimmune disorders such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus.
Another potential application of Acazicolcept Biosimilar is in the treatment of cancer. The CD28 receptor is expressed on various types of cancer cells, and its activation has been linked to tumor growth and progression. By targeting and activating the CD28 receptor on cancer cells, Acazicolcept Biosimilar can potentially inhibit tumor growth and enhance the immune response against cancer cells. This could be especially beneficial in combination with other cancer therapies, such as chemotherapy and immunotherapy.
Acazicolcept Biosimilar may also have applications in the treatment of infectious diseases. The CD28 receptor is involved in the activation of T cells, which play a crucial role in the immune response against pathogens. By targeting and activating the CD28 receptor, Acazicolcept Biosimilar can enhance the immune response and potentially aid in the treatment of infectious diseases, such as viral infections and bacterial infections.
In summary, Acazicolcept Biosimilar is a novel fusion protein that combines the anti-CD28 antibody with a therapeutic protein. Its structure allows for targeted delivery and activation of the CD28 receptor, leading to the activation of T cells and potential therapeutic benefits in autoimmune disorders, cancer, and infectious diseases. Further research and clinical trials are needed to fully explore the potential of Acazicolcept Biosimilar as a therapeutic agent.
ProteoGenix catalogue number PX-TA1999. For research use only.
Target: Acazicolcept Biosimilar – Anti-CD28 fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Acazicolcept Biosimilar – Anti-CD28 fusion protein – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
